## **Supplemental material**

## Table of Contents for the Supplemental Material

## Page

- **Supplemental Table 1**: Characteristics of 590 participants in the European Quality (EQUAL) study on treatment of older people with advanced chronic kidney disease at start of dialysis.
- **Supplemental Table 2**: The number (%) of patients who did or did not have a study visit of all included patients (n = 457) within each follow-up interval.
- **Supplemental Table 3**: Characteristics of 457 participants in the European Quality (EQUAL) study on treatment of older people with advanced chronic kidney disease at start of dialysis, stratified by the number of SF-36 questionnaires completed.
- 5-6 **Supplemental Table 4**: Evolution of mental and physical HRQoL in the year before and after start of dialysis within subgroups, adjusted for potential confounders.
  - **Supplemental Table 5**: Median (IQR) HRQoL scores at start of dialysis or within 30 days before start of dialysis in those who filled an SF-36 at that time.
  - **Supplemental Table 6**: Evolution of mental and physical health-related quality of life (HRQoL) with restriction of follow-up to 1 year before and 0.5 year after start of dialysis in 449 older patients.
  - **Supplemental Table 7**: Evolution of mental and physical health-related quality of life (HRQoL) with extension of follow-up to 3 years before and 1 year after start of dialysis in 496 older patients.
  - 9 Supplemental Figure 1: Flow diagram indicating the selection of EQUAL Study participants.
- **Supplemental Figure 2**: Histograms indicating the number of completed SF-36 questionnaires per dialysis patient in total (left) or during the year before or after start of dialysis (right).
- **Supplemental Figure 3**: Histogram indicating the number of completed and missing SF-36 questionnaires during the year before and after start of dialysis.
- **Supplemental Figure 4**: Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with additional knots at 3 [left] and 1 [right] months before and after start of dialysis in 457 older patients.
- **Supplemental Figure 5.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) in the year before and after start of dialysis in 457 older patients, with adjustments for age, sex, diabetes and cardiovascular disease in order to correct for HRQoL data missing at random explained by these variables.
- **Supplemental Figure 6.** Linear change of mental (blue) and physical (green) health-related quality of life (HRQoL) in the year before and after start of dialysis in 457 older patients, including a discontinuous change at start of dialysis.
- **Supplemental Figure 7.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with restriction of follow-up to 1 year before and 0.5 year after start of dialysis in 449 older patients.
- **Supplemental Figure 8.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with extension of follow-up to 3 years before and 1 year after start of dialysis in 496 older patients.

**Supplemental Table 1.** Characteristics of 590 participants in the European Quality (EQUAL) study on treatment of older people with advanced chronic kidney disease at start of dialysis.

	Included	Excluded
	n = 457	<i>n</i> = 133
Demographics		
Age (yr)	76 (6)	75 (6)
Men <i>, n</i> (%)	344 (75)	92 (69)
Clinical characteristics		
Primary kidney disease, n (%)		
Diabetes	111 (24)	36 (27)
Hypertension	124 (27)	37 (28)
Systemic / glomerular / tubulointerstitial	116 (25)	18 (14)
Other / unknown	106 (23)	40 (30)
Dialysis modality, <i>n</i> (%)		
Hemodialysis	315 (74)	75 (74)
Peritoneal dialysis	110 (26)	26 (26)
Diabetes <i>, n</i> (%)	199 (45)	65 (51)
Cardiovascular disease, n (%) <sup>a</sup>	200 (46)	53 (42)
Chronic lung disease, n (%)	53 (12)	21 (16)
Malignancy, n (%)	95 (22)	21 (17)
BMI (kg/m <sup>2</sup> )*	27 (6)	27 (3)
Systolic BP (mmHg)*	147 (24)	147 (24)
Diastolic BP (mmHg)*	74 (12)	74 (12)
Blood chemistry*		
Creatinine (mg/dL) <sup>c</sup>	6.6 (2.3)	6.3 (2.1)
eGFR (ml/min/1.73m <sup>2</sup> ) <sup>d</sup>	8 (3)	8 (3)
Urea nitrogen (mg/dL) <sup>e</sup>	92 (42)	109 (73)
Albumin (g/dL)	3.5 (0.6)	3.5 (0.8)
Cholesterol (mg/dL) <sup>f</sup>	158 (54)	143 (35)

Data are expressed as number (%) or mean (± standard deviation)

<sup>a</sup>Cardiovascular disease was defined as any history of a cerebral vascular accident, a myocardial infarction or peripheral vascular disease.

<sup>b</sup>Measured at start of dialysis or within 30 days before start of dialysis.

<sup>c</sup>To convert the values for creatinine to micromoles per liter, multiply by 88.40.

 $^{\rm d}{\rm eGFR}$  , was estimated based on serum creatinine using the CKD-EPI formula

<sup>e</sup>To convert the values for urea nitrogen to millimoles per liter, multiply by 0.3571.

<sup>f</sup>To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

Follow-up interval in months*	-12 to -9	-9 to -6	-6 to -3	-3 to 0	0 to +3	+3 to +6	+6 to +9	+9 to +12
<b>Study visit, <i>n</i> (%)</b> SF-36 completed	185 (40) 161 (87)	196 (43) 171 (87)	238 (52) 187 (79)	332 (73) 256 (77)	375 (82) 238 (63)	235 (51) 159 (68)	157 (34) 98 (62)	180 (39) 121 (67)
SF-36 missing	24 (13)	25 (13)	51 (21)	76 (23)	137 (37)	76 (32)	59 (38)	59 (33)
No study visit, <i>n</i> (%)**	272 (60)	261 (57)	219 (48)	125 (27)	82 (18)	222 (49)	300 (66)	277 (61)
Started during later interval Previous visit <6 months ago	147 (54) 125 (46)	100 (38) 159 (61)	61 (28) 156 (71)	2 (1) 122 (98)	- 80 (98)	- 216 (97)	- 282 (94)	- 176 (64)
Did not yet reach interval Died before scheduled visit	-	-	-	-	-	0 (0) 0 (0)	0 (0) 2 (1)	2 (1) 33 (12)
Stopped before scheduled visit Unexplained missing visit	- 0 (0)	- 2 (1)	- 2 (1)	- 1 (1)	- 2 (2)	0 (0) 6 (3)	1 (0) 15 (5)	26 (9) 40 (14)

**Supplemental Table 2.** The number (%) of patients who did or did not have a study visit of all included patients (n = 457) within each follow-up interval.

\* Month 0 = start of dialysis

\*\* For those who did not have a study visit, the reason for missing this visit is given: 1) the patient only started the EQUAL study at a later follow-up interval within the year before dialysis initiation; 2) the patient already had a visit during the 6 months before this follow-up interval, thus a new visit was not yet necessary; 3) the patient did not yet reach the corresponding follow-up interval after dialysis initiation at time of the data extraction; 4) the patient died before reaching the corresponding follow-up interval, 5) the patient stopped the study for other reasons before reaching the corresponding follow-up interval, 6) it was unclear why the patient had no study visit within the corresponding follow-up interval. Since these categories are mutually exclusive, the number of patients who died before a scheduled visit in this table (n = 33) differs from the total number of deaths (n = 74) observed in the year after dialysis. Of all patients who died, 41 (55%) had a previous visit <6 months ago before the last follow-up interval and were thus reported in the second category.

SF-36: 36-item Short-Form Health Survey

at start of dialysis, stratmed by the humber of	<4 SF-36	≥4 SF-36
	completed	completed
	n = 252	<i>n</i> = 205
Demographics		
Age (yr)	77 (7)	76 (6)
Men <i>, n</i> (%)	195 (77)	149 (73)
Clinical characteristics		
Primary kidney disease, n (%)		
Diabetes	61 (24)	50 (25)
Hypertension	67 (27)	57 (28)
Systemic / glomerular / tubulointerstitial	68 (27)	48 (23)
Other / unknown	56 (22)	50 (24)
Dialysis modality, n (%)		
Hemodialysis	176 (78)	139 (70)
Peritoneal dialysis	49 (22)	61 (30)
Charlson comorbidity score	7.2 (2.1)	6.6 (1.6)
Diabetes, n (%)	109 (44)	90 (45)
Cardiovascular disease, n (%) <sup>a</sup>	119 (50)	81 (41)
Chronic lung disease, n (%)	34 (14)	19 (9)
Malignancy, n (%)	62 (26)	33 (17)
BMI (kg/m²)*	27 (6)	27 (5)
Systolic BP (mmHg)*	147 (24)	148 (24)
Diastolic BP (mmHg)*	75 (12)	73 (12)
Blood chemistry*		
Creatinine (mg/dL)	6.5 (2.3)	6.9 (2.2)
eGFR (ml/min/1.73m²) <sup>b</sup>	8 (3)	7 (3)
Urea nitrogen (mg/dL)	90 (45)	92 (39)
Albumin (g/dL) (mean (SD))	3.5 (0.7)	3.5 (0.5)
Cholesterol (mg/dL)	162 (58)	154 (54)

**Supplemental Table 3.** Characteristics of 457 participants in the European Quality (EQUAL) study on treatment of older people with advanced chronic kidney disease at start of dialysis, stratified by the number of SF-36 questionnaires completed.

Data are expressed as number (%) or mean (± standard deviation)

<sup>a</sup>Cardiovascular disease was defined as any history of a cerebral vascular accident, a myocardial infarction or peripheral vascular disease.

<sup>b</sup>Measured at start of dialysis or within 30 days before start of dialysis.

<sup>c</sup>To convert the values for creatinine to micromoles per liter, multiply by 88.40.

<sup>d</sup>eGFR, was estimated based on serum creatinine using the CKD-EPI formula

<sup>e</sup>To convert the values for urea nitrogen to millimoles per liter, multiply by 0.3571.

<sup>f</sup>To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

**Supplemental Table 4**. Evolution of mental and physical HRQoL in the year before and after start of dialysis within subgroups, adjusted for potential confounders.

MCS		PCS change per year (95% CI)		
-	-	-	Year after dialysis	
-13 (-17 to -9)	+2 (-7 to +4)	-11 (-15 to -7)	-2 (-11 to +7)	
			-1 (-16 to +13)	
-14 (-20 to -9)	+0.0 (-13 to +13)	-12 (-17 to -7)	-1 (-13 to +11)	
			-1 (-16 to +13)	
-14 (-20 to -9)	+0.1 (-13 to +13)	-12 (-17 to -7)	-1.0 (-13 to +11)	
-14 (-18 to -9)	+2 (-9 to +12)	-11 (-15 to -7)	-3 (-13 to +7)	
-11 (-19 to -2)	+3 (-16 to +23)	-10 (-18 to -2)	+1 (-17 to +20)	
-16 (-23 to -10)	+2 (-14 to +19)	-12 (-18 to -6)	-4 (-19 to +11)	
			-0.6 (-13 to +12)	
			· · · · ·	
-16 (-23 to -10)	+3 (-13 to +19)	-12 (-18 to -6)	-3 (-18 to +11)	
			-0.2 (-13 to +13)	
( 00 0)	()	(,	0.1 ( 10 00 + 10)	
-15 (-21 to -8)	+6 (-11 to +23)	-12 (-18 to -5)	-2 (-18 to +14)	
. ,			-0.3 (-13 to +13)	
	. (,	(,		
-8 (-15 to -0.2)	$\pm 2(-16 \pm 0, \pm 20)$	-11 (-19 to -3)	-3 (-21 to +15)	
			-3 (-15 to +9)	
			+0.1 (-26 to +27)	
-28 (-40 (0 -10)	+5 (-20 (0 +50)	-22 (-33 (0 -12)	+0.1 (-20 t0 +27)	
$-7(-15 \pm 0.0)$	+2(-16 + 0 + 20)	-10 (-18 to -2)	-3 (-21 to +16)	
			-3 (-15 to +9)	
			+0.6 (-26 to +27)	
20 ( 40 (0 10)	13 ( 27 (0 130)	22 ( 33 (0 12)	10.0 ( 20 to 127)	
-7 (-14 to +0 9)	+2 (-16 to +20)	-10 (-17 to -2)	-2 (-21 to +16)	
			-3 (-15 to +9)	
-28 (-40 to -16)	+5 (-26 to +36)	-23 (-33 to -12)	+0.3 (-26 to +27)	
	Year before dialysis $-13 (-17 \text{ to } -9)$ $-11 (-17 \text{ to } -5)$ $-14 (-20 \text{ to } -9)$ $-11 (-17 \text{ to } -5)$ $-14 (-20 \text{ to } -9)$ $-11 (-17 \text{ to } -5)$ $-14 (-20 \text{ to } -9)$ $-11 (-17 \text{ to } -2)$ $-16 (-23 \text{ to } -10)$ $-11 (-17 \text{ to } -6)$ $-16 (-23 \text{ to } -10)$ $-11 (-17 \text{ to } -6)$ $-16 (-23 \text{ to } -10)$ $-11 (-17 \text{ to } -5)$ $-15 (-21 \text{ to } -8)$ $-12 (-17 \text{ to } -6)$ $-8 (-15 \text{ to } -0.2)$ $-14 (-20 \text{ to } -8)$ $-28 (-40 \text{ to } -16)$ $-7 (-15 \text{ to } +0.0)$ $-13 (-19 \text{ to } -8)$ $-28 (-40 \text{ to } -16)$ $-7 (-14 \text{ to } +0.9)$ $-13 (-19 \text{ to } -8)$	$\begin{array}{ccccc} -11 & (-17 \text{ to } -5) & +5 & (-10 \text{ to } +19) \\ -14 & (-20 \text{ to } -9) & +0.0 & (-13 \text{ to } +13) \\ \hline & -11 & (-17 \text{ to } -5) & +5 & (-10 \text{ to } +19) \\ -14 & (-20 \text{ to } -9) & +0.1 & (-13 \text{ to } +13) \\ \hline & -14 & (-18 \text{ to } -9) & +2 & (-9 \text{ to } +12) \\ -11 & (-19 \text{ to } -2) & +3 & (-16 \text{ to } +23) \\ \hline & -16 & (-23 \text{ to } -10) & +2 & (-14 \text{ to } +19) \\ -11 & (-17 \text{ to } -6) & +4 & (-10 \text{ to } +18) \\ \hline & -16 & (-23 \text{ to } -10) & +3 & (-13 \text{ to } +19) \\ -11 & (-17 \text{ to } -6) & +4 & (-10 \text{ to } +18) \\ \hline & -16 & (-23 \text{ to } -10) & +3 & (-13 \text{ to } +19) \\ -11 & (-17 \text{ to } -5) & +4 & (-10 \text{ to } +18) \\ \hline & -15 & (-21 \text{ to } -8) & +6 & (-11 \text{ to } +23) \\ -12 & (-17 \text{ to } -6) & +4 & (-10 \text{ to } +18) \\ \hline & -15 & (-21 \text{ to } -8) & +2 & (-11 \text{ to } +18) \\ \hline & -15 & (-21 \text{ to } -8) & +2 & (-11 \text{ to } +18) \\ \hline & -15 & (-21 \text{ to } -8) & +2 & (-11 \text{ to } +15) \\ -28 & (-40 \text{ to } -16) & +5 & (-26 \text{ to } +20) \\ -14 & (-20 \text{ to } -8) & +2 & (-16 \text{ to } +20) \\ -13 & (-19 \text{ to } -8) & +3 & (-10 \text{ to } +16) \\ -28 & (-40 \text{ to } -16) & +5 & (-27 \text{ to } +36) \\ \hline & -7 & (-14 \text{ to } +0.9) & +2 & (-16 \text{ to } +20) \\ -13 & (-19 \text{ to } -8) & +3 & (-10 \text{ to } +16) \\ \hline & -3 & (-10 \text{ to } +16) \\ \end{array}$	Year before dialysisYear after dialysisYear before dialysis $-13 (-17 \text{ to } -9)$ $+2 (-7 \text{ to } +4)$ $-11 (-15 \text{ to } -7)$ $-11 (-17 \text{ to } -5)$ $+5 (-10 \text{ to } +19)$ $-9 (-15 \text{ to } -3)$ $-14 (-20 \text{ to } -9)$ $+0.0 (-13 \text{ to } +13)$ $-12 (-17 \text{ to } -7)$ $-11 (-17 \text{ to } -5)$ $+5 (-10 \text{ to } +19)$ $-9 (-15 \text{ to } -3)$ $-14 (-20 \text{ to } -9)$ $+0.1 (-13 \text{ to } +13)$ $-12 (-17 \text{ to } -7)$ $-14 (-20 \text{ to } -9)$ $+0.1 (-13 \text{ to } +13)$ $-12 (-17 \text{ to } -7)$ $-14 (-18 \text{ to } -9)$ $+2 (-9 \text{ to } +12)$ $-11 (-15 \text{ to } -7)$ $-14 (-18 \text{ to } -9)$ $+2 (-9 \text{ to } +12)$ $-11 (-15 \text{ to } -7)$ $-11 (-19 \text{ to } -2)$ $+3 (-16 \text{ to } +23)$ $-10 (-18 \text{ to } -2)$ $-16 (-23 \text{ to } -10)$ $+3 (-13 \text{ to } +19)$ $-12 (-18 \text{ to } -6)$ $-11 (-17 \text{ to } -5)$ $+4 (-10 \text{ to } +18)$ $-11 (-16 \text{ to } -5)$ $-15 (-21 \text{ to } -8)$ $+6 (-11 \text{ to } +23)$ $-12 (-18 \text{ to } -5)$ $-15 (-21 \text{ to } -8)$ $+6 (-11 \text{ to } +23)$ $-12 (-18 \text{ to } -5)$ $-15 (-21 \text{ to } -8)$ $+6 (-11 \text{ to } +23)$ $-12 (-18 \text{ to } -3)$ $-14 (-20 \text{ to } -8)$ $+2 (-16 \text{ to } +20)$ $-11 (-19 \text{ to } -3)$ $-14 (-20 \text{ to } -8)$ $+2 (-16 \text{ to } +20)$ $-10 (-18 \text{ to } -3)$ $-28 (-40 \text{ to } -16)$ $+5 (-27 \text{ to } +36)$ $-22 (-33 \text{ to } -12)$ $-7 (-15 \text{ to } -0.0)$ $+2 (-16 \text{ to } +20)$ $-10 (-17 \text{ to } -2)$ $-13 (-19 \text{ to } -8)$ $+3 (-10 \text{ to } +16)$ $-22 (-33 \text{ to } -12)$	

History of diabetes [crude] yes, n = 200 $-15 (-21 \text{ to } -8)$ $-0.9 (-16 \text{ to } +14)$ $-9 (-14 \text{ to } -3)$ $-5 (-18 \text{ to } +9)$ no, n = 248 $-11 (-16 \text{ to } -7)$ $+6 (-6 \text{ to } +12)$ $-13 (-18 \text{ to } -8)$ $+0.6 (-11 \text{ to } +12)$ [age + sex]yes $-14 (-21 \text{ to } -8)$ $-0.8 (-16 \text{ to } +14)$ $-8 (-14 \text{ to } -2)$ $-4 (-10 \text{ to } +9)$ no $-11 (-16 \text{ to } -6)$ $+6 (-6 \text{ to } +18)$ $-13 (-18 \text{ to } -8)$ $+1 (-11 \text{ to } +13)$ [age + sex + smoking]yes $-14 (-21 \text{ to } -8)$ $-0.8 (-16 \text{ to } +14)$ $-8 (-14 \text{ to } -2)$ $-4 (-18 \text{ to } +9)$ no $-12 (-17 \text{ to } -7)$ $+6 (-6 \text{ to } +18)$ $-13 (-18 \text{ to } -8)$ $+2 (-10 \text{ to } +14)$ History of cardiovascular disease**///////////////////////////////				I	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	History of diabetes				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $					
$ \begin{bmatrix} \log e + sex \end{bmatrix} \\ \text{yes} \\ \text{no} \\ -14 (-21 \text{ to} -8) \\ -0.8 (-16 \text{ to} +14) \\ -13 (-18 \text{ to} -8) \\ +1 (-11 \text{ to} +13) \\ \end{bmatrix} \\ \begin{bmatrix} \log e + sex + smoking \end{bmatrix} \\ \text{yes} \\ \text{no} \\ -11 (-16 \text{ to} -6) \\ +6 (-6 \text{ to} +18) \\ -13 (-18 \text{ to} -8) \\ +1 (-11 \text{ to} +13) \\ \end{bmatrix} \\ \begin{bmatrix} \log e + sex + smoking \end{bmatrix} \\ \text{yes} \\ \text{no} \\ -12 (-17 \text{ to} -7) \\ +6 (-6 \text{ to} +18) \\ -13 (-18 \text{ to} -8) \\ +2 (-10 \text{ to} +14) \\ -3 (-18 \text{ to} -8) \\ +2 (-10 \text{ to} +14) \\ -3 (-18 \text{ to} -8) \\ +2 (-10 \text{ to} +14) \\ \end{bmatrix} \\ \\ \hline \\$	•				
yes $-14 (-21 to -8)$ $-0.8 (-16 to +14)$ $-8 (-14 to -2)$ $-4 (-10 to +9)$ no $-11 (-16 to -6)$ $+6 (-6 to +18)$ $-13 (-18 to -8)$ $+1 (-11 to +13)$ [age + sex + smoking]yes $-14 (-21 to -8)$ $-0.8 (-16 to +14)$ $-8 (-14 to -2)$ $-4 (-18 to +9)$ no $-12 (-17 to -7)$ $+6 (-6 to +18)$ $-3 (-18 to -8)$ $+2 (-10 to +14)$ History of cardiovascular disease** $-14 (-20 to -8)$ $-3 (-18 to +12)$ $-9 (-15 to -3)$ $-4 (-18 to +10)$ no, n = 237 $-12 (-17 to -8)$ $+7 (-6 to +19)$ $-13 (-18 to -8)$ $+2 (-10 to +14)$  age + sex] $-14 (-20 to -8)$ $-3 (-18 to +12)$ $-9 (-15 to -3)$ $-4 (-18 to +10)$ no $-11 (-16 to -6)$ $+7 (-5 to +19)$ $-13 (-18 to -8)$ $+2 (-10 to +14)$  age + sex] $-14 (-21 to -8)$ $-3 (-18 to +13)$ $-9 (-15 to -3)$ $-4 (-18 to +10)$ no $-11 (-16 to -6)$ $+7 (-5 to +19)$ $-13 (-18 to -8)$ $+2 (-10 to +14)$  age + sex + smoking + DM] $-14 (-19 to -8)$ $+5 (-8 to +18)$ $-15 (-20 to -9)$ $+0.8 (-12 to +13)$ $-7 n = 216$ $-14 (-19 to -8)$ $+5 (-8 to +18)$ $-15 (-20 to -9)$ $+0.6 (-12 to +13)$ $27 n = 232$ $-13 (-18 to -7)$ $-0.1 (-14 to +14)$ $-8 (-13 to -3)$ $-4 (-17 to +8)$ $[age + sex] -13 (-18 to -7)-0.2 (-14 to +14)-8 (-13 to -3)-4 (-17 to +8)27-126 (-19 to -9)+5 (-8 to +18)-15 (-20 to -9)+1 (-12 to +13)[age + sex] -13 $		-11 (-16 to -7)	+6 (-6 to +17)	-13 (-18 to -8)	+0.6 (-11 to +12)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	[age + sex]				
$ \begin{bmatrix} i \text{ ger } + \text{ sex } + \text{ smoking} \end{bmatrix} \\ \text{ yes } & 14 (21 \text{ to } -8) & -0.8 (-16 \text{ to } +14) \\ -12 (-17 \text{ to } -7) & +6 (-6 \text{ to } +18) & -13 (-18 \text{ to } -2) & -4 (-18 \text{ to } +9) \\ -13 (-18 \text{ to } -8) & +2 (-10 \text{ to } +14) \\ \end{bmatrix} \\  \hline \text{History of cardiovascular disease**} \\ \begin{bmatrix} \text{ fordel} \end{bmatrix} \\ \text{ yes, } n = 201 & 14 (-20 \text{ to } -8) & -3 (-18 \text{ to } +12) \\ no, n = 237 & 12 (-17 \text{ to } -8) & +7 (-6 \text{ to } +19) \\ no, n = 237 & 12 (-17 \text{ to } -8) & -3 (-18 \text{ to } +12) \\ no & -12 (-17 \text{ to } -8) & -3 (-18 \text{ to } +12) \\ no & -11 (-16 \text{ to } -6) & +7 (-5 \text{ to } +19) & -13 (-18 \text{ to } -8) \\ -13 (-18 \text{ to } -8) & +2 (-10 \text{ to } +14) \\ \hline \begin{bmatrix} \text{ lage } + \text{ sex} \end{bmatrix} \\ \text{ yes } & -14 (-20 \text{ to } -8) & -3 (-18 \text{ to } +12) \\ no & -11 (-16 \text{ to } -6) & +7 (-5 \text{ to } +19) & -13 (-18 \text{ to } -8) \\ -13 (-18 \text{ to } -7) & +2 (-10 \text{ to } +14) \\ \hline \begin{bmatrix} \text{ lage } + \text{ sex} \end{bmatrix} \\ \text{ yes } & -14 (-21 \text{ to } -8) & -3 (-18 \text{ to } +13) \\ -11 (-16 \text{ to } -6) & +7 (-5 \text{ to } +19) & -13 (-18 \text{ to } -7) \\ -13 (-18 \text{ to } -7) & +2 (-10 \text{ to } +14) \\ \hline \end{bmatrix} \\ \hline \text{ Charlson comorbidity index} \\ \begin{bmatrix} \text{ for udel} \\ \text{ cfrudel} \end{bmatrix} \\ \text{ sex} \end{bmatrix} \\ \text{ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -3 (-13 \text{ to } -3) & -4 (-17 \text{ to } +8) \\ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-18 \text{ to } +10) \\ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-18 \text{ to } +10) \\ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-18 \text{ to } +10) \\ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-18 \text{ to } +10) \\ -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-18 \text{ to } +10) \\ -10 (-15 \text{ to } -5) & -0.7 (-12 \text{ to } +13) \\ -10 (-15 \text{ to } -5) & -0.7 (-12 \text{ to } +13) \\ -27 & -13 (-18 \text{ to } -7) & -0.2 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -2) & -5 (-77 \text{ to } +8) \\ \hline \end{bmatrix} $ <b>Dialysis modality</b> \\ \text{ fermodialysis, n = 100 \\ \text{ ligge } + \text{ sex } + \text{ smoking } + 14 (-19 \text{ to } -9) & +3 (-9 \text{ to } +14) \\ -10 (-1	yes				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	no	-11 (-16 to -6)	+6 (-6 to +18)	-13 (-18 to -8)	+1 (-11 to +13)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	[age + sex + smoking]				
History of cardiovascular disease** [crude] yes, $n = 201$ no, $n = 237$ 	yes	-14 (-21 to -8)	-0.8 (-16 to +14)	-8 (-14 to -2)	-4 (-18 to +9)
$ \begin{bmatrix} crude^{1} \\ yes, n = 201 \\ no, n = 237 \\ (age + sex] \\ yes \\ yes \\ ves \\ no \\ n$	no	-12 (-17 to -7)	+6 (-6 to +18)	-13 (-18 to -8)	+2 (-10 to +14)
yes, $n = 201$ no, $n = 237$ [age + sex] $-14 (-20 \text{ to } -8)$ $-12 (-17 \text{ to } -8)$ $-3 (-18 \text{ to } +12)$ $+7 (-6 \text{ to } +19)$ $-9 (-15 \text{ to } -3)$ $-13 (-18 \text{ to } -8)$ $+2 (-10 \text{ to } +14)$ [age + sex] yes no $-14 (-20 \text{ to } -8)$ $-11 (-16 \text{ to } -6)$ $-3 (-18 \text{ to } +12)$ $-11 (-16 \text{ to } -6)$ $-9 (-15 \text{ to } -3)$ $-13 (-18 \text{ to } -8)$ $+2 (-10 \text{ to } +14)$ [age + sex] yes ves no $-14 (-20 \text{ to } -8)$ $-11 (-16 \text{ to } -6)$ $-3 (-18 \text{ to } +12)$ $-13 (-18 \text{ to } -8)$ $+7 (-5 \text{ to } +19)$ $-9 (-15 \text{ to } -3)$ $-13 (-18 \text{ to } -8)$ $-4 (-18 \text{ to } +10)$ $-13 (-18 \text{ to } -8)$ $+2 (-10 \text{ to } +14)$ Charlson comorbidity index [crude] $<7, n = 216$ $<7, n = 216$ $<7, n = 232$ $<7$ $<7$ $<7$ $=7$ $=7$ $=13 (-18 \text{ to } -7)$ $-13 (-18 \text{ to } -7)$ $-12 (-10 \text{ to } +14)$ [age + sex] $<7, n = 232$ $<7$ $<7$ $<7$ $-13 (-18 \text{ to } -7)$ $-13 (-18 \text{ to } -7)$ $-13 (-14 \text{ to } +14)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +8)$ [age + sex] $<7$ $<7$ $-13 (-18 \text{ to } -7)$ $-12 (-18 \text{ to } -7)$ $-12 (-14 \text{ to } +14)$ bialysis modality [crude] hemodialysis, $n = 325$ peritoneal dialysis $n = 100$ [age + sex] hemodialysis peritoneal dialysis $(-14 (-19 \text{ to } -9)$ $-13 (-20 \text{ to } -7)$ $-0.2 (-17 \text{ to } +16)$ (af exp + sex) hemodialysis hemodialysis-14 (-19 \text{ to } -9) hemodialysis-14 (-19 \text{ to } -9) hemodialysis	History of cardiovascular disease**				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	[crude]				
$ \begin{bmatrix} age + sex \\ yes \\ no \\ no \\ [age + sex + smoking + DM] \\ yes \\ no \\ n$	yes, <i>n</i> = 201	-14 (-20 to -8)	-3 (-18 to +12)	-9 (-15 to -3)	-4 (-18 to +10)
yes no $-14 (-20 \text{ to } -8)$ $-11 (-16 \text{ to } -6)$ $-3 (-18 \text{ to } +12)$ $+7 (-5 \text{ to } +19)$ $-9 (-15 \text{ to } -3)$ $-13 (-18 \text{ to } -8)$ $-4 (-18 \text{ to } +10)$ $-13 (-18 \text{ to } -8)$ <i>[age + sex + smoking + DM]</i> yes no $-14 (-21 \text{ to } -8)$ $-11 (-16 \text{ to } -6)$ $-3 (-18 \text{ to } +13)$ $+7 (-5 \text{ to } +19)$ $-9 (-15 \text{ to } -4)$ $-13 (-18 \text{ to } -7)$ $+2 (-10 \text{ to } +14)$ <b>Charlson comorbidity index</b> <i>[crude]</i> $<7, n = 216$ $27, n = 232$ $(7, n = 232)$ $(7, n = 232)$ $(-13 (-18 \text{ to } -7))$ $-14 (-19 \text{ to } -8)$ $(-13 (-18 \text{ to } -3))$ $-15 (-20 \text{ to } -9)$ $(-16 (-12 \text{ to } +13))$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +8)$ $(-17 \text{ to } +8)$ <i>[age + sex]</i> $<7$ $(-7, -7)$ $(-13 (-18 \text{ to } -7))$ $-13 (-14 \text{ to } +14)$ $-13 (-14 \text{ to } +14)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +8)$ <i>[age + sex + smoking]</i> $<7$ $(-7)$ $(-14 (-19 \text{ to } -9))$ $+13 (-18 \text{ to } -7)$ $-14 (-19 \text{ to } -9)$ $-13 (-14 \text{ to } +14)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +8)$ <i>Dialysis modality</i> <i>[crude]</i> hemodialysis, $n = 325$ $peritoneal dialysis, n = 100-13 (-20 \text{ to } -7)-3 (-9 \text{ to } +14)-10 (-15 \text{ to } -5)-0.7 (-12 \text{ to }+10)-15 (-21 \text{ to } -8)-7 (-23 \text{ to }+10)[age + sex]hemodialysisperitoneal dialysis(-14 (-19 \text{ to } -9)+3 (-9 \text{ to }+14)-10 (-15 \text{ to } -5)-0.4 (-11 \text{ to }+10)-13 (-20 \text{ to }-7)-0.2 (-17 \text{ to }+16)-10 (-15 \text{ to }-5)-0.4 (-11 \text{ to }+10)-13 (-20 \text{ to }-7)-0.2 (-16 \text{ to }+17)$	no, <i>n</i> = 237	-12 (-17 to -8)	+7 (-6 to +19)	-13 (-18 to -8)	+2 (-10 to +14)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	[age + sex]				
$ \begin{bmatrix} age + sex + smoking + DM \end{bmatrix} \\ yes \\ no \\ \end{bmatrix} \\ \begin{bmatrix} -14 (-21 \text{ to } -8) \\ -11 (-16 \text{ to } -6) \\ +7 (-6 \text{ to } +19) \\ \end{bmatrix} \\ \begin{bmatrix} -9 (-15 \text{ to } -4) \\ -13 (-18 \text{ to } -7) \\ +2 (-10 \text{ to } +14) \\ \end{bmatrix} \\ \begin{bmatrix} -14 (-19 \text{ to } -8) \\ +7 (-6 \text{ to } +19) \\ +7 (-6 \text{ to } +19) \\ \end{bmatrix} \\ \begin{bmatrix} -15 (-20 \text{ to } -9) \\ +2 (-10 \text{ to } +14) \\ -13 (-18 \text{ to } -7) \\ +2 (-10 \text{ to } +14) \\ \end{bmatrix} \\ \begin{bmatrix} -15 (-20 \text{ to } -9) \\ +2 (-10 \text{ to } +14) \\ -8 (-13 \text{ to } -3) \\ -4 (-17 \text{ to } +8) \\ -8 (-13 \text{ to } -3) \\ -4 (-17 \text{ to } +8) \\ \end{bmatrix} \\ \begin{bmatrix} -14 (-19 \text{ to } -8) \\ +5 (-8 \text{ to } +18) \\ -13 (-18 \text{ to } -7) \\ -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) \\ -4 (-17 \text{ to } +8) \\ \end{bmatrix} \\ \begin{bmatrix} -14 (-19 \text{ to } -9) \\ -13 (-18 \text{ to } -7) \\ -13 (-18 \text{ to } -7) \\ -12 (-18 \text{ to } -7) \\ -0.2 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -2) \\ -5 (-17 \text{ to } +8) \\ \end{bmatrix} \\ \end{bmatrix} \\ \begin{bmatrix} -10 (-15 \text{ to } -5) \\ -0.7 (-12 \text{ to } +10) \\ -15 (-21 \text{ to } -8) \\ -15 (-20 \text{ to } -9) \\ +1 (-12 \text{ to } +14) \\ -8 (-13 \text{ to } -2) \\ -5 (-17 \text{ to } +8) \\ \end{bmatrix} \\ \end{bmatrix} \\ \begin{bmatrix} Dialysis modality \\ [crude] \\ hemodialysis, n = 325 \\ peritoneal dialysis, n = 100 \\ -13 (-20 \text{ to } -7) \\ -14 (-19 \text{ to } -9) \\ -13 (-9 \text{ to } +14) \\ -10 (-15 \text{ to } -5) \\ -0.7 (-12 \text{ to } +10) \\ -15 (-21 \text{ to } -8) \\ -7 (-23 \text{ to } +10) \\ -15 (-21 \text{ to } -8) \\ -7 (-23 \text{ to } +10) \\ -13 (-20 \text{ to } -6) \\ -0.2 (-16 \text{ to } +17) \\ -14 (-19 \text{ to } -9) \\ -13 (-20 \text{ to } -6) \\ -0.2 (-16 \text{ to } +17) \\ -14 (-12 \text{ to } -7) \\ -10 (-15 \text{ to } -5) \\ -0.4 (-11 \text{ to } +10) \\ -15 (-23 \text{ to } +11) \\ \begin{bmatrix} age + sex + smoking + DM + CVD \end{bmatrix} \\ hemodialysis \\ -13 (-18 \text{ to } -8) \\ +4 (-9 \text{ to } +16) \\ -10 (-15 \text{ to } -6) \\ -0.8 (-10 \text{ to } +12) \\ \end{bmatrix} $	yes	· · ·		. ,	-
yes no $-14 (-21 \text{ to } -8)$ $-11 (-16 \text{ to } -6)$ $-3 (-18 \text{ to } +13)$ $+7 (-6 \text{ to } +19)$ $-9 (-15 \text{ to } -4)$ $-13 (-18 \text{ to } -7)$ $-4 (-18 \text{ to } +10)$ $+2 (-10 \text{ to } +14)$ Charlson comorbidity index [crude] $< 7, n = 216$ $27, n = 232$ $(7 n = 232)$ $-14 (-19 \text{ to } -8)$ $-13 (-18 \text{ to } -7)$ $+5 (-8 \text{ to } +18)$ $-13 (-14 \text{ to } +14)$ $-15 (-20 \text{ to } -9)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +13)$ $-8 (-13 \text{ to } -3)$ $<7$ $< 7$ $< 14 (-19 \text{ to } -9)$ $-12 (-18 \text{ to } -7)$ $-0.1 (-14 \text{ to } +14)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +9)$ $-8 (-12 \text{ to } +13)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +9)$ $-4 (-17 \text{ to } +9)$ $-8 (-12 \text{ to } +13)$ $-8 (-13 \text{ to } -3)$ $-4 (-17 \text{ to } +9)$ $-4 (-17 \text{ to } +9)$ $-10 (-15 \text{ to } -3)$ $-4 (-17 \text{ to } +9)$ Dialysis modality [crude] hemodialysis, $n = 325$ peritoneal dialysis, $n = 100$ $13 (-20 \text{ to } -7)$ $-13 (-20 \text{ to } -7)$ $-0.2 (-17 \text{ to } +16)$ $-10 (-15 \text{ to } -5)$ $-0.7 (-12 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ $-7 (-23 \text{ to } +10)$ $-13 (-20 \text{ to } -6)$ $-13 (-20 \text{ to } -6)$ $-13 (-16 \text{ to } +17)$ $-10 ($		-11 (-16 to -6)	+7 (-5 to +19)	-13 (-18 to -8)	+2 (-10 to +14)
no $-11(-16 \text{ to } -6)$ $+7(-6 \text{ to } +19)$ $-13(-18 \text{ to } -7)$ $+2(-10 \text{ to } +14)$ Charlson comorbidity index [crude] $<7, n = 216$ $-14(-19 \text{ to } -8)$ $+5(-8 \text{ to } +18)$ $-15(-20 \text{ to } -9)$ $+0.8(-12 \text{ to } +13)$ $27, n = 232$ $-13(-18 \text{ to } -7)$ $-0.1(-14 \text{ to } +14)$ $-8(-13 \text{ to } -3)$ $-4(-17 \text{ to } +8)$ [age + sex] $-13(-19 \text{ to } -8)$ $+5(-8 \text{ to } +18)$ $-14(-19 \text{ to } -9)$ $+0.6(-12 \text{ to } +13)$ $27$ $-13(-18 \text{ to } -7)$ $-0.1(-14 \text{ to } +14)$ $-8(-13 \text{ to } -3)$ $-4(-17 \text{ to } +9)$ [age + sex + smoking] $-13(-18 \text{ to } -7)$ $-0.1(-14 \text{ to } +14)$ $-8(-13 \text{ to } -3)$ $-4(-17 \text{ to } +9)$ $(age + sex + smoking]$ $-12(-18 \text{ to } -7)$ $-0.2(-14 \text{ to } +14)$ $-8(-13 \text{ to } -3)$ $-1(-12 \text{ to } +14)$ Dialysis modality $(crude]$ $-12(-18 \text{ to } -7)$ $-0.2(-14 \text{ to } +14)$ $-10(-15 \text{ to } -5)$ $-0.7(-12 \text{ to } +10)$ $[age + sex]$ $-14(-19 \text{ to } -9)$ $+3(-9 \text{ to } +14)$ $-10(-15 \text{ to } -5)$ $-0.7(-12 \text{ to } +10)$ $[age + sex]$ $-14(-19 \text{ to } -9)$ $+3(-9 \text{ to } +14)$ $-10(-15 \text{ to } -5)$ $-0.4(-11 \text{ to }+10)$ $[age + sex + smoking + DM + CVD]$ $-13(-18 \text{ to } 8)$ $+4(-9 \text{ to }+16)$ $-10(-15 \text{ to } -6)$ $-0.8(-10 \text{ to }+12)$	[age + sex + smoking + DM]				
$\begin{array}{c c} \textbf{Charlson comorbidity index} \\ [crude] \\ <7, n = 216 \\ 27, n = 232 \\ 7, n = 232 \\ (-14 (-19 \text{ to } -8) + 5 (-8 \text{ to } +18) + -15 (-20 \text{ to } -9) + 0.8 (-12 \text{ to } +13) \\ -13 (-18 \text{ to } -7) + 0.1 (-14 \text{ to } +14) + -8 (-13 \text{ to } -3) + 4 (-17 \text{ to } +8) \\ [age + sex] \\ <7 \\ <7 \\ 7 \\ (-13 (-19 \text{ to } -8) + 5 (-8 \text{ to } +18) + -14 (-19 \text{ to } -9) + 0.6 (-12 \text{ to } +13) \\ -13 (-18 \text{ to } -7) + 0.1 (-14 \text{ to } +14) + -8 (-13 \text{ to } -3) + 4 (-17 \text{ to } +9) \\ [age + sex + smoking] \\ <7 \\ <7 \\ 7 \\ (-14 (-19 \text{ to } -9) + 5 (-8 \text{ to } +18) + -15 (-20 \text{ to } -9) + 1 (-12 \text{ to } +14) \\ -12 (-18 \text{ to } -7) + 0.2 (-14 \text{ to } +14) + -8 (-13 \text{ to } -3) + 4 (-17 \text{ to } +9) \\ \hline \textbf{Dialysis modality} \\ [crude] \\ \text{hemodialysis, n = 325 } \\ \text{retioneal dialysis, n = 100 } \\ [age + sex] \\ \text{hemodialysis } \\ -13 (-20 \text{ to } -7) + 0.2 (-17 \text{ to } +16) + -10 (-15 \text{ to } -5) + 0.7 (-12 \text{ to } +10) \\ -15 (-21 \text{ to } -8) + 7 (-23 \text{ to } +10) \\ [age + sex] \\ \text{hemodialysis } \\ -13 (-20 \text{ to } -6) + 0.2 (-16 \text{ to } +17) + 14 (-21 \text{ to } -7) + 0.4 (-11 \text{ to } +10) \\ -13 (-20 \text{ to } -6) + 0.2 (-16 \text{ to } +17) + 14 (-21 \text{ to } -7) + 0.4 (-11 \text{ to } +10) \\ -14 (-21 \text{ to } -7) + 0.4 (-11 \text{ to } +10) \\ -14 (-21 \text{ to } -7) + 0.4 (-11 \text{ to } +10) \\ -14 (-21 \text{ to } -7) + 0.4 (-10 \text{ to } +12) \\ \hline \textbf{hemodialysis} \\ \hline \textbf{hemodialysis} \\ -13 (-18 \text{ to } -8) + 4 (-9 \text{ to } +16) + -10 (-15 \text{ to } -6) + 0.8 (-10 \text{ to } +12) \\ \hline \textbf{hemodialysis} \\ \hline $	yes			· · ·	• •
$ \begin{bmatrix} crude \end{bmatrix} & -14 (-19 \text{ to } -8) & +5 (-8 \text{ to } +18) \\ 27, n = 232 & -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ [age + sex] & -13 (-19 \text{ to } -8) & +5 (-8 \text{ to } +18) \\ -38 (-13 \text{ to } -3) & -4 (-17 \text{ to } +8) \\ \hline \\ gae + sex] & -13 (-19 \text{ to } -8) & +5 (-8 \text{ to } +18) \\ -7 & -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-17 \text{ to } +9) \\ \hline \\ gae + sex + smoking] & -14 (-19 \text{ to } -9) & +5 (-8 \text{ to } +18) \\ -7 & -13 (-18 \text{ to } -7) & -0.1 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -3) & -4 (-17 \text{ to } +9) \\ \hline \\ gae + sex + smoking] & -14 (-19 \text{ to } -9) & +5 (-8 \text{ to } +18) \\ -7 & -12 (-18 \text{ to } -7) & -0.2 (-14 \text{ to } +14) \\ -8 (-13 \text{ to } -2) & -5 (-17 \text{ to } +8) \\ \hline \\ \end{bmatrix} $	no	-11 (-16 to -6)	+7 (-6 to +19)	-13 (-18 to -7)	+2 (-10 to +14)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Charlson comorbidity index				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	[crude]				
$ \begin{bmatrix} age + sex \end{bmatrix} \\ <7 \\ >7 \\ >7 \\ =7 \\ (age + sex + smoking] \\ <7 \\ <7 \\ >7 \\ >7 \\ >7 \\ >7 \\ >7 \\ >7$	<7, <i>n</i> = 216	-14 (-19 to -8)	+5 (-8 to +18)	-15 (-20 to -9)	+0.8 (-12 to +13)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	≥7, <i>n</i> = 232	-13 (-18 to -7)	-0.1 (-14 to +14)	-8 (-13 to -3)	-4 (-17 to +8)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	[age + sex]				
$ \begin{bmatrix} age + sex + smoking \end{bmatrix} \\ <7 \\ \geq7 \end{bmatrix} +1 (-12 \text{ to } -9) +5 (-8 \text{ to } +18) \\ -12 (-18 \text{ to } -7) +0.2 (-14 \text{ to } +14) + -8 (-13 \text{ to } -2) +1 (-12 \text{ to } +14) \\ -8 (-13 \text{ to } -2) +5 (-17 \text{ to } +8) \end{bmatrix} $	<7	-13 (-19 to -8)	+5 (-8 to +18)	-14 (-19 to -9)	+0.6 (-12 to +13)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	≥7	-13 (-18 to -7)	-0.1 (-14 to +14)	-8 (-13 to -3)	-4 (-17 to +9)
$ \ge 7 \qquad -12 (-18 \text{ to } -7) \qquad -0.2 (-14 \text{ to } +14) \qquad -8 (-13 \text{ to } -2) \qquad -5 (-17 \text{ to } +8) $	[age + sex + smoking]				
Dialysis modality [crude] hemodialysis, $n = 325$ peritoneal dialysis, $n = 100$ $-14 (-19 \text{ to } -9)$ $-13 (-20 \text{ to } -7)$ $+3 (-9 \text{ to } +14)$ $-0.2 (-17 \text{ to } +16)$ $-10 (-15 \text{ to } -5)$ $-15 (-21 \text{ to } -8)$ $-0.7 (-12 \text{ to } +10)$ $-15 (-21 \text{ to } -8)$ [age + sex] hemodialysis $-14 (-19 \text{ to } -9)$ $-13 (-20 \text{ to } -7)$ $+3 (-9 \text{ to } +14)$ $-10 (-15 \text{ to } -5)$ $-0.4 (-11 \text{ to } +10)$ $-10 (-15 \text{ to } -5)$ [age + sex] hemodialysis $-14 (-19 \text{ to } -9)$ $-13 (-20 \text{ to } -6)$ $-0.2 (-16 \text{ to } +17)$ $-10 (-15 \text{ to } -5)$ $-14 (-21 \text{ to } -7)$ [age + sex + smoking + DM + CVD] hemodialysis $-13 (-18 \text{ to } -8)$ $+4 (-9 \text{ to } +16)$ $-10 (-15 \text{ to } -6)$ $-10 (-15 \text{ to } -6)$ $-0.8 (-10 \text{ to } +12)$	<7	-14 (-19 to -9)	+5 (-8 to +18)	-15 (-20 to -9)	+1 (-12 to +14)
	≥7	-12 (-18 to -7)	-0.2 (-14 to +14)	-8 (-13 to -2)	-5 (-17 to +8)
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Dialysis modality				
peritoneal dialysis, n = 100       -13 (-20 to -7)       -0.2 (-17 to +16)       -15 (-21 to -8)       -7 (-23 to +10)         [age + sex]       -14 (-19 to -9)       +3 (-9 to +14)       -10 (-15 to -5)       -0.4 (-11 to +10)         peritoneal dialysis       -13 (-20 to -6)       -0.2 (-16 to +17)       -14 (-21 to -7)       -6 (-23 to +11)         [age + sex + smoking + DM + CVD]       -13 (-18 to -8)       +4 (-9 to +16)       -10 (-15 to -6)       -0.8 (-10 to +12)	[crude]				
[age + sex]       -14 (-19 to -9)       +3 (-9 to +14)       -10 (-15 to -5)       -0.4 (-11 to +10)         peritoneal dialysis       -13 (-20 to -6)       -0.2 (-16 to +17)       -14 (-21 to -7)       -6 (-23 to +11)         [age + sex + smoking + DM + CVD]       -13 (-18 to -8)       +4 (-9 to +16)       -10 (-15 to -6)       -0.8 (-10 to +12)	hemodialysis, <i>n</i> = 325	-14 (-19 to -9)	+3 (-9 to +14)	-10 (-15 to -5)	-0.7 (-12 to +10)
hemodialysis       -14 (-19 to -9)       +3 (-9 to +14)       -10 (-15 to -5)       -0.4 (-11 to +10)         peritoneal dialysis       -13 (-20 to -6)       -0.2 (-16 to +17)       -14 (-21 to -7)       -6 (-23 to +11)         [age + sex + smoking + DM + CVD]       -13 (-18 to -8)       +4 (-9 to +16)       -10 (-15 to -6)       -0.8 (-10 to +12)	peritoneal dialysis, <i>n</i> = 100	-13 (-20 to -7)	-0.2 (-17 to +16)	-15 (-21 to -8)	-7 (-23 to +10)
peritoneal dialysis       -13 (-20 to -6)       -0.2 (-16 to +17)       -14 (-21 to -7)       -6 (-23 to +11)         [age + sex + smoking + DM + CVD]       -13 (-18 to -8)       +4 (-9 to +16)       -10 (-15 to -6)       -0.8 (-10 to +12)	[age + sex]				
[age + sex + smoking + DM + CVD] hemodialysis -13 (-18 to -8) +4 (-9 to +16) -10 (-15 to -6) -0.8 (-10 to +12)	hemodialysis	-14 (-19 to -9)	+3 (-9 to +14)	-10 (-15 to -5)	-0.4 (-11 to +10)
hemodialysis -13 (-18 to -8) +4 (-9 to +16) -10 (-15 to -6) -0.8 (-10 to +12)	peritoneal dialysis	-13 (-20 to -6)	-0.2 (-16 to +17)	-14 (-21 to -7)	-6 (-23 to +11)
	[age + sex + smoking + DM + CVD]				
peritoneal dialysis -13 (-20 to -7) +0.9 (-15 to +18) -15 (-22 to -8) -5 (-22 to +12)	hemodialysis	-13 (-18 to -8)	+4 (-9 to +16)	-10 (-15 to -6)	-0.8 (-10 to +12)
	peritoneal dialysis	-13 (-20 to -7)	+0.9 (-15 to +18)	-15 (-22 to -8)	-5 (-22 to +12)

\*Subgroup status determined at start of dialysis

\*\*Defined as a history of cerebrovascular disease, myocardial infarction or peripheral vascular disease

	indez at of within 50 days before start of darysis		
Subgroup	Median MCS (IQR)	Median PCS (IQR)	
Total with SF-36 available, $n = 199^*$	53 (38-73)	39 (27-58)	
Age			
≥65 - <75 years, <i>n</i> = 85	56 (41-74)	38 (28-59)	
≥75 years, <i>n</i> = 114	51 (37-72)	40 (27-55)	
Sex			
men <i>, n</i> = 157	54 (40-74)	42 (29-64)	
women, <i>n</i> = 42	45 (34-61)	29 (23-37)	
eGFR (CKD-EPI)			
≥10 ml/min/1.73m², <i>n</i> = 106	51 (34-75)	40 (28-57)	
<10 ml/min/1.73m <sup>2</sup> , <i>n</i> = 83	59 (43-72)	40 (26-57)	
Smoking status			
never smoker, <i>n</i> = 57	58 (41-75)	38 (29-56)	
ex smoker, <i>n</i> = 102	49 (34-71)	42 (28-65)	
current smoker, <i>n</i> = 21	46 (38-66)	41 (35-50)	
History of diabetes			
yes, <i>n</i> = 88	55 (38-73)	37 (27-57)	
no, <i>n</i> = 107	51 (38-73)	41 (28-57)	
History of cardiovascular disease**			
yes, <i>n</i> = 88	55 (37-71)	38 (29-57)	
no, <i>n</i> = 104	51 (38-73)	40 (24-56)	
Charlson comorbidity index			
<7, n = 97	54 (41-76)	42 (29-69)	
≥7, <i>n</i> = 98	51 (34-69)	38 (24-54)	
Dialysis modality			
hemodialysis, n = 140	50 (35-69)	38 (27-54)	
peritoneal dialysis, <i>n</i> = 53	54 (43-78)	43 (28-70)	

**Supplemental Table 5.** Median (IQR) HRQoL scores at start of dialysis or within 30 days before start of dialysis in those who filled an SF-36 at that time.

\*Since not all patients completed an SF-36 questionnaire at start of dialysis or within 30 days before start of dialysis, this information was only available for 199 (44%) of the 457 included patients. \*\*Defined as a history of cerebrovascular disease, myocardial infarction or peripheral vascular disease. **Supplemental Table 6.** Evolution of mental and physical health-related quality of life (HRQoL) with restriction of follow-up to 1 year before and 0.5 year after start of dialysis in 449 older patients.


	Mental HRQoL	Physical HRQoL
	change (95% CI)	change (95% CI)
1 year before start of dialysis	-13 (-17 to -9)	-11 (-15 to -7)
0.5 year after start of dialysis	+11 (+3 to +19)	+6 (-8 to +20)

**Supplemental Table 7.** Evolution of mental and physical health-related quality of life (HRQoL) with extension of follow-up to 3 years before and 1 year after start of dialysis in 496 older patients.

	Mental HRQoL	Physical HRQoL
	change (95% CI)	change (95% CI)
3 years before start of dialysis	-20 (-23 to -16)	-19 (-23 to -15)
1 year after start of dialysis	+2 (-2 to +6)	-3 (-7 to +2)


Total of **1736** EQUAL participants, meeting the following criteria:

- age ≥ 65 years
- nephrology referred
- no history of kidney replacement therapy
- first drop in eGFR < 20 mL/min/1.73m<sup>2</sup>



**Supplemental Figure 1.** Flow diagram indicating the selection of EQUAL Study participants.

eGFR: estimated glomerular filtration rate, SF-36: 36-item Short-Form Health Survey




Total number of SF-36 completed per dialysis patient

Number of SF-36 completed per dialysis patient before or after dialysis initiation


**Supplemental Figure 2.** Histograms indicating the number of completed SF-36 questionnaires per dialysis patient in total (left) or during the year before or after start of dialysis (right).

SF-36: 36-item Short-Form Health Survey



**Supplemental Figure 3.** Histogram indicating the number of completed and missing SF-36 questionnaires during the year before and after start of dialysis.


SF-36: 36-item Short-Form Health Survey



**Supplemental Figure 4.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with additional knots at 3 [left] and 1 [right] months before and after start of dialysis in 457 older patients.

HRQoL: health-related quality of life, SF-36: 36-item Short-Form Health Survey


**Supplemental Figure 5.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) in the year before and after start of dialysis in 457 older patients, with adjustments for age, sex, diabetes and cardiovascular disease in order to correct for HRQoL data missing at random explained by these variables.



Mental and Physcial HRQoL

HRQoL: health-related quality of life, SF-36: 36-item Short-Form Health Survey


**Supplemental Figure 6.** Linear change of mental (blue) and physical (green) health-related quality of life (HRQoL) in the year before and after start of dialysis in 457 older patients, including a discontinuous change at start of dialysis.



Mental and Physcial HRQoL

HRQoL: health-related quality of life, SF-36: 36-item Short-Form Health Survey


**Supplemental Figure 7.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with restriction of follow-up to 1 year before and 0.5 year after start of dialysis in 449 older patients.



Mental and Physical HRQoL

HRQoL: health-related quality of life, SF-36: 36-item Short-Form Health Survey

**Supplemental Figure 8.** Evolution of mental (blue) and physical (green) health-related quality of life (HRQoL) with extension of follow-up to 3 years before and 1 year after start of dialysis in 496 older patients.



Mental and Physical HRQoL

HRQoL: health-related quality of life, SF-36: 36-item Short-Form Health Survey